With over 17 years’ health economics experience, Ray leads health economic projects, principally focused on developing decision-analytic models for use during pricing and reimbursement negotiations. These models range from complex HTA models suitable for NICE, CADTH and PBAC, to simple budget impact models for use during formulary discussions. Ray also develops early-stage models for strategic planning and gap analysis, conducts burden of illness studies for HTA assessments, and supports RCT and observational study design so appropriate data is collected for economic analyses. His experience covers Europe, Australia, Asia, and North America, and several therapy areas including oncology, multiple sclerosis, respiratory disease, infectious disease, CVD, and diabetes.
Ray was previously associate principal at QuintilesIMS Global Consulting, specializing in health economics. He has also held roles as European HEOR director at Astellas, UK HEOR team leader at Boehringer Ingelheim, technical lead for economic evaluation at Heron Evidence Development, and head of quantitative risk assessment at the Health Protection Agency (now Public Health England).
Ray has presented studies at international conferences and authored publications for Nature, Emerging Infectious Diseases, Journal of Economics, PharmacoEconomics, Heart, and Value in Health. Dr. Gani has a PhD in economic modelling from the University of Strathclyde, an MSc in mathematical modelling from the University College London, and a BSc (Hons) in mathematics from the University of Leicester.